Brought to you by 
Immusol to participate in Pfizer's research project Pfizergen
13 Jul 1999
Executive Summary
Immusol will be one of four biotechnology companies that will participate in Pfizer's genome research project, Pfizergen, aimed at accelerating drug discovery by understanding the human genetic map. The deal could be worth $49 million to Immusol.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Antisense, Oligonucleotides
- Gene Therapy, Cell Therapy
- Large Molecule
-
Drug Discovery Tools
- Genomics-Proteomics
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Equity
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Immusol to participate in Pfizer's research project Pfizergen
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice